NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Aptose Biosciences Inc (NASDAQ: APTO)

 
APTO Technical Analysis
5
As on 9th Jun 2023 APTO STOCK Price closed @ 5.56 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 0.97 & Strong Buy for SHORT-TERM with Stoploss of 1.29 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

APTOSTOCK Price

Open 5.61 Change Price %
High 5.65 1 Day -0.11 -1.94
Low 5.44 1 Week 5.14 1223.81
Close 5.56 1 Month 5.08 1058.33
Volume 60174 1 Year 4.06 270.67
52 Week High 6.34 | 52 Week Low 0.41
 
NASDAQ USA Most Active Stocks
TSLA 244.40 4.06%
TTOO 0.07 -12.50%
SOFI 8.18 0.74%
FFIE 0.33 6.45%
PONO 1.72 2.38%
AMD 124.92 3.20%
IDEX 0.06 0.00%
NKLA 0.70 14.75%
AMZN 123.43 -0.66%
AAPL 180.96 0.22%
 
NASDAQ USA Top Gainers Stocks
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
NDRAW 0.03 200.00%
METXW 0.05 150.00%
GLSPT 33.43 138.62%
BCAC 22.71 125.30%
JCIC 22.08 116.68%
AURCW 0.04 100.00%
NOVVW 0.02 100.00%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
PTIXW 0.01 -66.67%
AGBAW 0.02 -66.67%
MLACW 0.02 -60.00%
MILEW 0.06 -53.85%
RCRTW 0.02 -50.00%
LOTZW 0.01 -50.00%
GSMGW 0.01 -50.00%
DKDCW 0.01 -50.00%
 
 
APTO
Daily Charts
APTO
Intraday Charts
Whats New @
Bazaartrend
APTO
Free Analysis
 
APTO Important Levels Intraday
RESISTANCE5.96
RESISTANCE5.83
RESISTANCE5.75
RESISTANCE5.67
SUPPORT5.45
SUPPORT5.37
SUPPORT5.29
SUPPORT5.16
 
APTO Forecast April 2024
4th UP Forecast6.43
3rd UP Forecast6.15
2nd UP Forecast5.98
1st UP Forecast5.81
1st DOWN Forecast5.31
2nd DOWN Forecast5.14
3rd DOWN Forecast4.97
4th DOWN Forecast4.69
 
APTO Weekly Forecast
4th UP Forecast5.95
3rd UP Forecast5.82
2nd UP Forecast5.75
1st UP Forecast5.67
1st DOWN Forecast5.45
2nd DOWN Forecast5.37
3rd DOWN Forecast5.30
4th DOWN Forecast5.17
 
APTO Forecast2024
4th UP Forecast17.58
3rd UP Forecast13.73
2nd UP Forecast11.34
1st UP Forecast8.96
1st DOWN Forecast2.16
2nd DOWN Forecast-0.22
3rd DOWN Forecast-2.61
4th DOWN Forecast-6.46
 
 
APTO Other Details
Segment EQ
Market Capital 192129216.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
APTO Address
APTO
 
APTO Latest News
 
Your Comments and Response on Aptose Biosciences Inc
 
APTO Business Profile
Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in the United States. Its clinical programs is APTO-253, which is a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory blood cancers, including acute myeloid leukemia and high-risk myelodysplastic syndrome. It has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806 and CG-806, which are in Phase 1a/b clinical trial for the treatment of patients with chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed/refractory acute myeloid leukemia. The company also has an agreement with OHM Oncology for the development, manufacture, and commercialization of APL-581, a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor program. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. Address: 251 Consumers Road, Toronto, ON, Canada, M2J 4R3
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service